US60770K1079 - Common Stock
NASDAQ:MRNA (2/3/2023, 12:48:08 PM)-1.73 (-0.98%)
|GICS Sector||Health Care|
|Earnings (Last)||11-03 2022-11-03/bmo||Earnings (Next)||02-22 2023-02-22|
|Ins Owners||5.42%||Inst Owners||63.95%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Cambridge, Massachusetts and currently employs 2,700 full-time employees. The company went IPO on 2018-12-07. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The company is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The firm develops technologies that enable the development of mRNA medicines for diverse applications. The company has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The firm develops technologies that enable the development of mRNA medicines.
200 Technology Sq
Cambridge MASSACHUSETTS 02139
CEO: Stephane Bancel
These stocks all fell by double digits last year.
The company is starting the year on a strong note.
Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy.
For those seeking the best discounts in the tech-centered index, these are the most undervalued Nasdaq stocks to buy.
Here you can normally see the latest stock twits on MRNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.